Renaissance Technologies LLC boosted its position in Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating) by 93.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 330,773 shares of the life sciences company’s stock after buying an additional 159,913 shares during the quarter. Renaissance Technologies LLC owned 0.40% of Integra LifeSciences worth $14,012,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in the company. Texas Permanent School Fund lifted its holdings in Integra LifeSciences by 0.4% in the 2nd quarter. Texas Permanent School Fund now owns 51,833 shares of the life sciences company’s stock worth $2,801,000 after buying an additional 191 shares in the last quarter. Money Concepts Capital Corp lifted its holdings in Integra LifeSciences by 2.3% in the 3rd quarter. Money Concepts Capital Corp now owns 9,095 shares of the life sciences company’s stock worth $385,000 after buying an additional 205 shares in the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Integra LifeSciences by 1.1% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 21,216 shares of the life sciences company’s stock worth $899,000 after buying an additional 227 shares in the last quarter. Commerce Bank lifted its holdings in Integra LifeSciences by 2.2% in the 3rd quarter. Commerce Bank now owns 10,971 shares of the life sciences company’s stock worth $465,000 after buying an additional 239 shares in the last quarter. Finally, Inspire Investing LLC increased its position in shares of Integra LifeSciences by 6.9% in the 2nd quarter. Inspire Investing LLC now owns 3,890 shares of the life sciences company’s stock worth $210,000 after purchasing an additional 252 shares during the last quarter. Institutional investors and hedge funds own 87.60% of the company’s stock.
Insiders Place Their Bets
In other Integra LifeSciences news, EVP Lisa Evoli sold 3,767 shares of the company’s stock in a transaction dated Monday, February 27th. The shares were sold at an average price of $57.00, for a total value of $214,719.00. Following the completion of the transaction, the executive vice president now owns 18,605 shares in the company, valued at approximately $1,060,485. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.20% of the stock is owned by insiders.
Integra LifeSciences Price Performance
Integra LifeSciences (NASDAQ:IART – Get Rating) last announced its quarterly earnings data on Wednesday, February 22nd. The life sciences company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.93 by $0.01. Integra LifeSciences had a net margin of 11.59% and a return on equity of 16.51%. The business had revenue of $398.00 million during the quarter, compared to the consensus estimate of $398.57 million. During the same quarter in the prior year, the firm earned $0.84 EPS. The company’s revenue for the quarter was down 1.8% compared to the same quarter last year. On average, sell-side analysts anticipate that Integra LifeSciences Holdings Co. will post 3.48 EPS for the current year.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on IART. Morgan Stanley boosted their target price on shares of Integra LifeSciences from $50.00 to $59.00 and gave the stock an “equal weight” rating in a research report on Friday, January 6th. Truist Financial boosted their target price on shares of Integra LifeSciences from $52.00 to $58.00 and gave the stock a “hold” rating in a research report on Tuesday, December 20th. TheStreet raised shares of Integra LifeSciences from a “c+” rating to a “b-” rating in a research report on Tuesday, December 27th. Finally, Citigroup dropped their target price on shares of Integra LifeSciences from $60.00 to $59.00 and set a “neutral” rating for the company in a research report on Thursday, February 23rd. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, Integra LifeSciences presently has a consensus rating of “Hold” and a consensus target price of $58.17.
About Integra LifeSciences
Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company’s neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care, such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment, and the precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices.
Featured Stories
- Get a free copy of the StockNews.com research report on Integra LifeSciences (IART)
- MarketBeat Week in Review – 2/27 – 3/3
- The 3 Most Upgraded Stocks Are Reversing
- How to Find Blue Chip Dividend Stocks
- Zscaler, Inc Plummets, Is It Time To Buy The Dip?
- What is a Good Dividend Yield? How to Decide
Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Co. (NASDAQ:IART – Get Rating).
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
